1 Recommendations

1.1 Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:

  • in people with intermediate‑2 or high-risk disease, and

  • if the company provides ruxolitinib with the discount agreed in the patient access scheme.

1.2 People whose treatment with ruxolitinib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)